JAK2 and essential thrombocythemia: Disease outcomes are similar to those of JAK2 V617F-positive patients. MPL mutation is observed in 3% of ET cases and 7% of PM cases and in the presence of MPL mutations, older age, higher platelet count and erythropoietin levels, lower hemoglobin, and bone marrow cellularity are seen.